Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biemond syndrome type 2 (BS2) is a rare genetic neurological and developmental disorder reported in a very small number of patients with a poorly defined phenotype which includes iris coloboma, short stature, obesity, hypogonadism, postaxial polydactyly, and intellectual disability. Hydrocephalus and facial dysostosis were also reported. BS2 shares features with Bardet-Biedl syndrome. There have been no further descriptions in the literature since 1997.
Features include: Preaxial hand polydactyly, Abnormality of the endocrine system, Short stature, and Hydrocephalus and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 2 | Hydrocephalus, Intellectual disability |
Arms and legs |
Biomarker and diagnostic research for Biemond syndrome type 2 has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Biemond syndrome type 2.
120 publications have been identified in PubMed for Biemond syndrome type 2. Research spans Case Report / Case Series (48%), Basic Science / Preclinical (17%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 57 | 48% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:45 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Biemond syndrome type 2
1 |
Preaxial hand polydactyly |
Hormones | 1 | Abnormality of the endocrine system |
Growth and development | 1 | Short stature |
20 |
17% |
Disease patterns and progression | 20 | 17% |
Research summaries | 19 | 16% |
Other research | 1 | 1% |
Testing and diagnosis research | 1 | 1% |
Clinical study results | 1 | 1% |
New treatment approaches | 1 | 1% |
Ali AMH (2026). [PMID: 42046702](https://pubmed.ncbi.nlm.nih.gov/42046702/). *Int Med Case Rep J*. [Case Report / Case Series]
Pomeroy JJ (2026). [PMID: 42175648](https://pubmed.ncbi.nlm.nih.gov/42175648/). *Am J Med Genet A*. [Review / Meta-Analysis]
Aziz A (2026). [PMID: 41832542](https://pubmed.ncbi.nlm.nih.gov/41832542/). *J Med Case Rep*. [Case Report / Case Series]
Chamarthi VS (2026). [PMID: 34424641](https://pubmed.ncbi.nlm.nih.gov/34424641/). *Unknown Journal*. [Review / Meta-Analysis]
Mokhtari A (2026). [PMID: 40842263](https://pubmed.ncbi.nlm.nih.gov/40842263/). *Clin Genet*. [Basic Science / Preclinical]
Barnes CJ (2026). [PMID: 33232075](https://pubmed.ncbi.nlm.nih.gov/33232075/). *Unknown Journal*. [Basic Science / Preclinical]
Schening J (2026). [PMID: 42110121](https://pubmed.ncbi.nlm.nih.gov/42110121/). *JPGN Rep*. [Case Report / Case Series]
Xian S (2026). [PMID: 42256993](https://pubmed.ncbi.nlm.nih.gov/42256993/). *Clin Case Rep*. [Basic Science / Preclinical]
Payne E (2026). [PMID: 41984002](https://pubmed.ncbi.nlm.nih.gov/41984002/). *J Hand Surg Am*. [Epidemiology / Natural History]
Abola MV (2026). [PMID: 41037671](https://pubmed.ncbi.nlm.nih.gov/41037671/). *J Pediatr Orthop*. [Epidemiology / Natural History]
AI-curated news mentioning Biemond syndrome type 2
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.